Blog
Siltuximab: Exploring IL-6 Inhibition in Castleman’s Disease and Research
Quick Facts About SiltuximabWhat is Siltuximab?Siltuximab is a monoclonal antibody targeting interleukin-6 (IL-6), a cytokine involved in inflammation and immune regulation.What is the m
…
16th Jan 2025
Sacituzumab: Exploring its Role in Cancer Research and the Rise of Biosimilars
Key Facts About SacituzumabWhat is Sacituzumab?Sacituzumab is an antibody-drug conjugate (ADC) that targets the tumor-associated antigen Trop-2, used to treat various cancers, including
…
16th Jan 2025
Brentuximab: Unveiling the Role of Anti-CD30 in Cancer Research
Key Facts About BrentuximabWhat is Brentuximab?Brentuximab is a monoclonal antibody targeting CD30, commonly used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell
…
15th Jan 2025
Gemtuzumab: Advancing CD33-Targeted Therapies in AML Research
Key Facts About GemtuzumabWhat is Gemtuzumab?Gemtuzumab is an antibody-drug conjugate (ADC) targeting CD33, a protein expressed on the surface of myeloid cells. It is widely recognized f
…
15th Jan 2025
Indatuximab: Advancing CD138-Targeted Therapy in Cancer Research
What You Need to Know About IndatuximabWhat is Indatuximab?Indatuximab ravtansine is an experimental monoclonal antibody-drug conjugate (ADC) that targets CD138, a protein highly express
…
14th Jan 2025
Girentuximab: Exploring Its Mechanism, Clinical Potential, and Research Advancements
Quick Facts About GirentuximabWhat is Girentuximab?Girentuximab is a monoclonal antibody targeting carbonic anhydrase IX (CAIX), predominantly expressed in renal cell carcinoma (RCC) cel
…
10th Dec 2024